| Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease M Gaggini, M Morelli, E Buzzigoli, RA DeFronzo, E Bugianesi, ... Nutrients 5 (5), 1544-1560, 2013 | 1039 | 2013 |
| Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects A Gastaldelli, K Cusi, M Pettiti, J Hardies, Y Miyazaki, R Berria, ... Gastroenterology 133 (2), 496-506, 2007 | 746 | 2007 |
| Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance M Gaggini, F Carli, C Rosso, E Buzzigoli, M Marietti, V Della Latta, ... Hepatology 67 (1), 145-158, 2018 | 380 | 2018 |
| Visceral fat in hypertension: influence on insulin resistance and β-cell function AM Sironi, A Gastaldelli, A Mari, D Ciociaro, V Postano, E Buzzigoli, ... Hypertension 44 (2), 127-133, 2004 | 378 | 2004 |
| Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein G Basta, AM Sironi, G Lazzerini, S Del Turco, E Buzzigoli, A Casolaro, ... The Journal of Clinical Endocrinology & Metabolism 91 (11), 4628-4634, 2006 | 265 | 2006 |
| Gut to brain interaction in Autism Spectrum Disorders: a randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters E Santocchi, L Guiducci, F Fulceri, L Billeci, E Buzzigoli, F Apicella, ... BMC psychiatry 16, 1-16, 2016 | 217 | 2016 |
| Impact of increased visceral and cardiac fat on cardiometabolic risk and disease AM Sironi, R Petz, D De Marchi, E Buzzigoli, D Ciociaro, V Positano, ... Diabetic Medicine 29 (5), 622-627, 2012 | 158 | 2012 |
| Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis A Gastaldelli, Y Miyazaki, M Pettiti, E Buzzigoli, S Mahankali, E Ferrannini, ... The Journal of Clinical Endocrinology & Metabolism 89 (8), 3914-3921, 2004 | 139 | 2004 |
| The effect of pioglitazone on the liver: role of adiponectin A Gastaldelli, Y Miyazaki, A Mahankali, R Berria, M Pettiti, E Buzzigoli, ... Diabetes care 29 (10), 2275-2281, 2006 | 104 | 2006 |
| Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease C Rosso, L Mezzabotta, M Gaggini, F Salomone, R Gambino, A Marengo, ... Hepatology 63 (1), 107-116, 2016 | 84 | 2016 |
| Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs P Iozzo, MJ Jarvisalo, J Kiss, R Borra, GA Naum, A Viljanen, T Viljanen, ... Gastroenterology 132 (2), 531-542, 2007 | 83 | 2007 |
| Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD I Pierantonelli, C Rychlicki, L Agostinelli, DM Giordano, M Gaggini, ... Scientific reports 7 (1), 12200, 2017 | 82 | 2017 |
| Effects of adding exercise to a 16-week very low-calorie diet in obese, insulin-dependent type 2 diabetes mellitus patients M Snel, A Gastaldelli, DM Ouwens, MKC Hesselink, G Schaart, ... The Journal of Clinical Endocrinology & Metabolism 97 (7), 2512-2520, 2012 | 81 | 2012 |
| Glucokinase links Krüppel‐like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease LP Bechmann, A Gastaldelli, D Vetter, GL Patman, L Pascoe, ... Hepatology 55 (4), 1083-1093, 2012 | 76 | 2012 |
| Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes A Gastaldelli, A Casolaro, M Pettiti, M Nannipieri, D Ciociaro, S Frascerra, ... Clinical Pharmacology & Therapeutics 81 (2), 205-212, 2007 | 76 | 2007 |
| Visceral fat and beta cell function in non-diabetic humans A Gastaldelli, AM Sironi, D Ciociaro, V Positano, E Buzzigoli, D Giannessi, ... Diabetologia 48, 2090-2096, 2005 | 66 | 2005 |
| 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study P Iozzo, A Gastaldelli, MJ Järvisalo, J Kiss, R Borra, E Buzzigoli, ... Journal of nuclear medicine 47 (6), 1016-1022, 2006 | 57 | 2006 |
| 40th EASD Annual Meeting of the European Association for the Study of Diabetes: Munich, Germany, 5–9 September 2004 M Veitenhansl, K Stegner, FX Hierl, C Dieterle, H Feldmeier, B Gutt, ... Diabetologia 47, A1-A464, 2004 | 51 | 2004 |
| Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients A Gastaldelli, A Casolaro, D Ciociaro, S Frascerra, M Nannipieri, ... American Journal of Physiology-Endocrinology and Metabolism 297 (1), E225-E230, 2009 | 36 | 2009 |
| The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF G Scabia, I Barone, M Mainardi, G Ceccarini, M Scali, E Buzzigoli, ... Scientific reports 8 (1), 1781, 2018 | 32 | 2018 |
